Influenza News and Research RSS Feed - Influenza News and Research

Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Scientists at the University of Texas Medical Branch were recognized with prestigious awards for their contributions in research at the annual American Society of Tropical Medicine and Hygiene meeting. [More]
Researchers discover a new way to combat influenza virus infection

Researchers discover a new way to combat influenza virus infection

The influenza virus, like all viruses, is a hijacker. It quietly slips its way inside cells, steals the machinery inside to make more copies of itself, and then -- having multiplied -- bursts out of the cell to find others to infect. [More]
A new method for determining onset of elevated influenza activity at community level

A new method for determining onset of elevated influenza activity at community level

Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts. [More]
Flusurvey to offer self-administered nasal swab to all participants

Flusurvey to offer self-administered nasal swab to all participants

People taking part in this year’s Flusurvey, the UK’s biggest crowd-sourced study of influenza will for the first time be offered a swab to confirm if their symptoms are caused by a flu virus or not as part of a new collaboration with i-sense. Data from social media and internet searches will also be combined with Flusurvey, allowing flu trends to be monitored across the UK more accurately and earlier than ever before. [More]
'Spillover' of henipaviruses into humans underway, study finds

'Spillover' of henipaviruses into humans underway, study finds

Another family of viruses, deadly in some cases, may have already jumped from fruit bats into humans in Africa, according to a study published today in the journal Nature Communications. The study provides the first, preliminary scientific evidence that "spillover" of henipaviruses into human populations is underway. [More]
Scientists call for public to help monitor spread of flu across the UK

Scientists call for public to help monitor spread of flu across the UK

People taking part in this year's Flusurvey, the UK's biggest crowd-sourced study of influenza will for the first time be offered a swab to confirm if their symptoms are caused by a flu virus or not as part of a new collaboration with i-sense. Data from social media and internet searches will also be combined with Flusurvey, allowing flu trends to be monitored across the UK more accurately and earlier than ever before. [More]
Three-day global symposium on Ebola virus, other infectious diseases

Three-day global symposium on Ebola virus, other infectious diseases

The 11th annual International Consortium on Anti-Virals (ICAV) symposium, Infectious Diseases: Global Public-Health Challenges of the Next Decade, will put the challenges posed by several infectious diseases under the microscope, including the Ebola virus, the H7N9 influenza virus, MERS coronavirus and dengue viruses, as well as drug-resistant tuberculosis. [More]
Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Critical care is defined by life-threatening conditions, which require close evaluation, monitoring, and treatment by appropriately trained health professionals. Cardiovascular care bears these same requirements. [More]
Survey: Majority of U.S. adult women do not believe that they are up to date on vaccinations

Survey: Majority of U.S. adult women do not believe that they are up to date on vaccinations

A national survey from Rite Aid and National Foundation for Infectious Diseases reveals that the majority of adult women living in the United States do not believe they are up to date on vaccinations to protect against many preventable diseases. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]
LSTM awarded research grants to develop Experimental Human Pneumococcal Carriage model

LSTM awarded research grants to develop Experimental Human Pneumococcal Carriage model

Respiratory specialists at Liverpool School Tropical Medicine have been awarded two substantial research grants to further develop and utilise their Experimental Human Pneumococcal Carriage (EHPC) model. [More]
Researchers synthetize molecules to block virus that causes influenza A

Researchers synthetize molecules to block virus that causes influenza A

The influenza A virus is a contagious and severe respiratory infection that affects animals but also humans. Researchers from the University of Barcelona have synthetized some molecules which are able to block the virus that causes influenza A and some of the mutations that make it resistant to common drugs. [More]
BIOVISION's 10th edition to focus on today’s health challenges

BIOVISION's 10th edition to focus on today’s health challenges

BIOVISION, the annual life sciences forum organized by the Foundation for the University of Lyon, today announces its 10thedition, which will take place on April 15 and 16, 2015 at the Musée des Confluences in Lyon, France. [More]
FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

FDA approves Fluzone High-Dose vaccine sBLA to include efficacy data in Prescribing Information

Sanofi Pasteur, the vaccines division of Sanofi, today announced that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for Fluzone High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. [More]
University of Adelaide-led project develops new test to eradicate H5N1 bird flu

University of Adelaide-led project develops new test to eradicate H5N1 bird flu

A University of Adelaide-led project has developed a new test that can distinguish between birds that have been vaccinated against the H5N1 strain of avian influenza virus or "bird flu" with those that have been naturally infected. [More]

Google search data can provide more accurate real time picture of flu

Researchers have found that Google search data really can provide a more accurate real time picture of current flu infections. [More]
Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'. [More]
Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation. [More]
MinuteClinic enters into clinical collaboration agreement with Lifespan

MinuteClinic enters into clinical collaboration agreement with Lifespan

MinuteClinic, the retail medical clinic of CVS Health, and Lifespan, Rhode Island's largest health system, which includes five partner hospitals and multiple physician groups, announced today that they have entered into a clinical collaboration agreement. [More]